Going forward, the strategy for many key players has been to deprioritize bipolar disorder as the market is becoming increasingly genericized. Key products in the portfolios of Janssen, Eli Lilly, and AstraZeneca now face generic competition, and the companies do not have any pipeline candidates to offset the decline in sales. Allergan/Lundbeck/Meiji Seika’s Saphris demonstrates the competitive nature of the current bipolar disorder treatment landscape. The drug has a superior safety profile compared to many other atypical agents, and its sublingual formulation is unique in this market. However, the drug’s limited clinical advantages do not justify its high cost compared to the more affordable generic versions of older agents. Consequently, the product has generated limited revenue to date, with sales of just $57.9m in 2014.
GlobalData’s PharmaPoint: Bipolar Disorder – Global Drug Forecast and Market Analysis to 2024 provides an overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.
Single user price: $10,995